Study points to HALP score as prognostic marker in canine MUE
Bottom line
A new retrospective study in Frontiers in Veterinary Science suggests the HALP score, calculated from hemoglobin, albumin, lymphocyte, and platelet values, may help predict short-term mortality in dogs with meningoencephalitis of unknown etiology, or MUE. Researchers evaluated 36 dogs and found HALP scores were significantly higher in survivors than non-survivors at both three months and one year. The score showed good predictive performance, with an area under the curve of 0.79 for three-month mortality and 0.80 for one-year mortality. Dogs with a HALP score of 12.25 or lower had a median survival of 31 days, compared with 283 days for dogs above that threshold. (frontiersin.org)
Why it matters: MUE remains a high-stakes diagnosis with variable outcomes, and clinicians have had limited, inconsistent prognostic tools to guide early conversations and monitoring. Prior work has linked poorer outcomes to factors such as obtundation at presentation, seizures, higher neurologic deficit scores, CSF abnormalities, hyperlactatemia, and some MRI findings, but prognostication is still difficult in practice. Because HALP uses routine bloodwork rather than advanced imaging or CSF-specific markers, it could offer a practical, non-invasive way to stratify risk early, if the findings hold up in larger cohorts. (frontiersin.org)
What to watch: The next question is whether larger, prospective studies validate HALP and show how it performs alongside established clinical, MRI, and CSF prognostic indicators. (frontiersin.org)
Key facts
- Study type
- Retrospective study
- Journal
- Frontiers in Veterinary Science
- Condition
- Meningoencephalitis of unknown etiology, or MUE
- Sample size
- 36 dogs
- Score evaluated
- HALP score, based on hemoglobin, albumin, lymphocyte, and platelet values
- Key finding
- HALP scores were significantly higher in survivors than non-survivors at three months and one year
- Three-month AUC
- 0.79
- One-year AUC
- 0.80
- Cutoff and survival
- HALP 12.25 or lower was linked to median survival of 31 days, versus 283 days above that threshold
A newly published study in Frontiers in Veterinary Science points to a simple blood-based score as a possible prognostic tool for dogs with meningoencephalitis of unknown etiology. In a retrospective review of 36 dogs with MUE, investigators found the HALP score, based on hemoglobin, albumin, lymphocyte, and platelet values, was significantly higher in survivors than in non-survivors at both three months and one year after diagnosis. The authors reported good predictive accuracy for both time points, suggesting HALP may help identify dogs at higher near-term risk using data many clinicians already collect. (frontiersin.org)
That matters because MUE is still one of the more challenging inflammatory neurologic diseases in small animal practice. It carries a guarded prognosis, and the first few months after diagnosis are often the most critical. Reviews of the literature note that reduced mentation, seizures, higher neurologic deficit severity, elevated or neutrophilic CSF cell counts, hyperlactatemia, and certain MRI findings have all been associated with worse outcomes, but those signals have not been fully consistent across studies. (frontiersin.org)
In the new study, the three-month mortality cut-off for HALP was 12.25, which produced 50.0% sensitivity and 95.0% specificity. For one-year mortality, the cut-off was 34.33, with 95.2% sensitivity and 66.7% specificity. Survival differences between low- and high-score groups were substantial: dogs with HALP scores at or below 12.25 had a median survival of 31 days, versus 283 days for dogs above that threshold, while dogs at or below 34.33 had a median survival of 67.5 days, versus 971 days for those above it. The study was received March 31, 2026, accepted May 19, 2026, and is currently posted by Frontiers ahead of the final formatted version. (frontiersin.org)
The findings also land in a broader search for accessible biomarkers in canine MUE. Earlier studies have explored blood and CSF markers, but results have been mixed. One prior study on acute phase proteins concluded that routinely assessed serum inflammatory parameters were not useful for predicting short-term outcome in MUO, while other work has looked at neutrophil-to-lymphocyte ratio more as a diagnostic biomarker than a prognostic one. That gives HALP a potentially distinct role: not as a disease-specific test, but as a practical risk-stratification tool derived from routine clinicopathologic data. (pmc.ncbi.nlm.nih.gov)
I didn’t find outside expert commentary specific to this new HALP paper, but the broader literature helps frame the result. A recent review described prognosis in MUO as guarded and emphasized that currently reported prognostic indicators are varied and imperfect. Another retrospective study of 98 dogs found obtundation at presentation increased the odds of death up to 6.6-fold in the first week, underscoring how much clinicians still rely on clinical impression and presentation severity when discussing prognosis with pet parents. (frontiersin.org)
Why it matters: For veterinary professionals, the appeal of HALP is its simplicity. If validated, it could help support triage decisions, intensity of monitoring, and earlier, more grounded prognosis discussions with pet parents, especially in referral settings where MUE cases often require rapid treatment choices before long-term response is clear. It may also be useful in research as a standardized baseline risk marker. At the same time, the study was small, retrospective, and based on a single cohort, so it’s not ready to replace neurologic exam findings, imaging, CSF analysis, or clinical judgment. (frontiersin.org)
What to watch: The key next step is external validation in larger, prospective populations, ideally with direct comparison against other prognostic indicators and treatment variables. It will also be worth watching whether HALP performs consistently across MUE subtypes, practice settings, and immunosuppressive protocols, or whether it works best as part of a multi-factor prognostic model rather than as a standalone score. (frontiersin.org)